| Sign In to gain access to subscriptions and/or personal tools. |
Biological Treatment of Vein Grafts and Stents in Lower-Extremity Arterial ReconstructionColumbia University College of Physicians and Surgeons, Columbia/Weill Cornell Division of Vascular Surgery, the New York Presbyterian Hospital, New York, njm2106@ columbia.edu Longevity of lower-extremity revascularization procedures has typically been limited because of restenosis of grafts, as well as stents and other percutaneous techniques. The ability to prevent or ameliorate neointimal hyperplasia and improve durability of lower-extremity arterial reconstruction is the focus of significant scientific and clinical research. The transcription factor decoy edifoligide was investigated as a potential inhibitor of neointimal hyperplasia, but the results of the pivotal clinical trial did not demonstrate significant improvement in graft reintervention, although secondary patency was improved. Similar to the coronary circulation, drug-eluting stents are a potential tool for prevention of restenosis after percutaneous arterial reconstruction. The SIROCCO study did not demonstrate improvement in superficial femoral artery stent patency with sirolimus-eluting stents. Studies are underway that are investigating paclitaxel-eluting stents for use in the superficial femoral artery. Other potential mediators of restenosis include absorbable drug-eluting stents and antibody-coated stents designed to promote endothelialization of the stent or graft surface. In addition, absorbable wraps eluting paclitaxel can be used at arterial and arteriovenous anastomoses to prevent restenosis. Clinical trials investigating these novel technologies are underway.
Key Words: vein graft • stent • restenosis
Perspectives in Vascular Surgery and Endovascular Therapy, Vol. 19, No. 3,
293-297 (2007) |
|||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
